Eledon Pharmaceuticals Inc’s (ELDN) Stock: A Long-Term Performance Analysis

In the past week, ELDN stock has gone down by -20.28%, with a monthly gain of 1.81% and a quarterly plunge of -10.11%. The volatility ratio for the week is 9.79%, and the volatility levels for the last 30 days are 8.84% for Eledon Pharmaceuticals Inc The simple moving average for the past 20 days is -6.19% for ELDN’s stock, with a 12.50% simple moving average for the past 200 days.

Is It Worth Investing in Eledon Pharmaceuticals Inc (NASDAQ: ELDN) Right Now?

The stock has a 36-month beta value of 0.93. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

The public float for ELDN is 22.85M, and at present, short sellers hold a 0.16% of that float. On April 04, 2024, the average trading volume of ELDN was 76.21K shares.

ELDN) stock’s latest price update

The stock of Eledon Pharmaceuticals Inc (NASDAQ: ELDN) has decreased by -12.44 when compared to last closing price of 1.93.Despite this, the company has seen a loss of -20.28% in its stock price over the last five trading days. GlobeNewsWire reported 2023-11-29 that IRVINE, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C.

Analysts’ Opinion of ELDN

Many brokerage firms have already submitted their reports for ELDN stocks, with Cantor Fitzgerald repeating the rating for ELDN by listing it as a “Overweight.” The predicted price for ELDN in the upcoming period, according to Cantor Fitzgerald is $15 based on the research report published on May 13, 2022 of the previous year 2022.

Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see ELDN reach a price target of $25. The rating they have provided for ELDN stocks is “Overweight” according to the report published on March 23rd, 2021.

ELDN Trading at -5.59% from the 50-Day Moving Average

After a stumble in the market that brought ELDN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -42.71% of loss for the given period.

Volatility was left at 8.84%, however, over the last 30 days, the volatility rate increased by 9.79%, as shares surge +3.05% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -2.87% lower at present.

During the last 5 trading sessions, ELDN fell by -20.28%, which changed the moving average for the period of 200-days by +2.42% in comparison to the 20-day moving average, which settled at $1.8040. In addition, Eledon Pharmaceuticals Inc saw -6.11% in overturn over a single year, with a tendency to cut further losses.

Stock Fundamentals for ELDN

The total capital return value is set at -0.35. Equity return is now at value -48.12, with -36.88 for asset returns.

Based on Eledon Pharmaceuticals Inc (ELDN), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -103.2. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is 127.22.

Currently, EBITDA for the company is -42.63 million with net debt to EBITDA at 0.1. The liquidity ratio also appears to be rather interesting for investors as it stands at 14.41.


To sum up, Eledon Pharmaceuticals Inc (ELDN) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts